Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by duskwon Nov 15, 2012 2:26pm
408 Views
Post# 20605933

RE: RE: SOME QUICK HEM NUMBERS

RE: RE: SOME QUICK HEM NUMBERS

I don't know if P/E of 15x is reasonable. There has been too much volatility. I think something around 10x is more reasonable.

That said, there is a lot of risk in their plan moving forward. They need to sell a money loosing business to capitalize. Otherwise, they will be forced to issue new shares which further dilutes EPS.

Conservatively, if they are able to show some progress and some good pro forma numbers throughout Q4 and Q1 next year, I think $1.00 is reasonable to see come April/May.

However, even so, I think if they can sell the entire company for $1.00 today they should do it! Personally I would take it, along with many other shareholders I'm guessing. I'd rather have $1.00 today than the potential of $2.00 in a year from now.

FWIW, Paradigm isn't drinking the kool-aid: 

Hemisphere GPS Inc : Paradigm Capital cuts target price to C$0.60 from C$0.70

Bullboard Posts